These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3229945)

  • 21. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
    Ardizzoni A; Rosso R; Salvati F; Fusco V; Cinquegrana A; De Palma M; Serrano J; Pennucci MC; Soresi E; Crippa M
    Cancer; 1991 Jun; 67(12):2984-7. PubMed ID: 2044044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
    Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
    Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
    Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
    J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
    J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Anand A; Anand A; Anand N
    Cancer; 1996 May; 77(9):1959-60. PubMed ID: 8646700
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
    Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
    J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
    Hunt KJ; Longton G; Williams MA; Livingston RB
    Chest; 1996 May; 109(5):1239-42. PubMed ID: 8625674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
    Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G
    Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.
    Tueni E; Sculier JP; Klastersky J
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):963-7. PubMed ID: 3044803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
    O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
    Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
    Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
    Harvey VJ; Slevin ML; Ponder BA; Blackshaw AJ; Wrigley PF
    Cancer; 1984 Sep; 54(6):961-4. PubMed ID: 6467141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
    Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
    Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
    Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
    J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
    Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
    Zidar BL; Metch B; Balcerzak SP; Pierce HI; Militello L; Keppen MD; Berenberg JL
    Cancer; 1992 Nov; 70(10):2547-51. PubMed ID: 1423183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
    Zimm S; Cleary SM; Lucas WE; Weiss RJ; Markman M; Andrews PA; Schiefer MA; Kim S; Horton C; Howell SB
    Cancer Res; 1987 Mar; 47(6):1712-6. PubMed ID: 3815369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.